Review · PMID 41241376

Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease

Short review naming KPV among host defense peptides proposed for inflammatory bowel disease; context, not new KPV data.

Last updated · 2025 · Rodrigues JM, Ferreira Leal AP, Buccini DF, Franco OL · Drug Discovery Today

Key findings

Short review of host defense peptides (HDPs) as candidate treatments for IBD
KPV is listed as an example of an alpha-MSH-derived HDP
HDPs are described as downregulating NF-κB, modulating cytokine release and restoring homeostasis
The authors suggest HDPs could reduce the side effects seen with current IBD treatments

Where to buy KPV →BioLongevity Labs · save 15% code VIALBASE

Citation: Rodrigues JM, Ferreira Leal AP, Buccini DF, Franco OL. Drug Discov Today. 2025;30(12):104535. PubMed

Review Scope

A short review, not an original study, of host defense peptides (HDPs) as candidate treatments for inflammatory bowel disease (IBD)
Starts from the point that current IBD treatments often have adverse effects, creating a need for alternatives
HDP classes covered: cathelicidins (e.g. LL-37-Tα1, KR-12), defensins (e.g. HD-5, hBD2), cecropins, microcins, brevinins, proline-rich antimicrobial peptides (PrAMPs), type V peptides, and alpha-melanocyte-stimulating hormone (α-MSH) derivatives
KPV is cited as the α-MSH example

Mechanisms Described (for HDPs as a group)

Downregulate the NF-κB pathway
Modulate cytokine release
Restore homeostasis
The authors conclude HDPs have therapeutic potential for IBD and could offer a way to reduce side effects

Relevance

This review places KPV among peptides being explored for IBD. The mechanisms above are described for HDPs as a class, not measured for KPV in this paper, and the review reports no new experimental data. Use it as landscape context alongside primary KPV studies.

Review Scope

Mechanisms Described (for HDPs as a group)

Relevance

See Also